Sophorolipids
Sophorolipids have been known for more than 40 years, yet they have garnered much public interest as of late as renewable biosurfactants due to their biodegradability and low ecotoxicity (Van Bogaert et.al., 2007) . Sophorolipids are produced as complex mixtures containing both the free acid and lactone forms. ese mixtures are typically brown oils, which are viscous and denser than water. Acidic sophorolipids naturally have better solubility and foaming power as compared to their lactonic form (Shin JD et. al, 2010) . Also, sophorolipids bene t the organisms that produce them as they aid in the solubility and thus accessibility of lipophilic substrates (Vedaraman N et. al., 2010) . e acidic and lactone forms of sophorolipids determine its properties as well as speci c applications. Acetylated lactonic sophorolipids had shown commercial and scienti c importance as they show biocide activity, anticancer activity and have been used in cosmetics as antidandru , bacteriostatic agents, deodorant, shampoo and moisturizing agent.
ey also act as agents for stimulating skin broblast metabolism. Acidic sophorolipids have been used in various therpeutic applications for skin diseases, such as in brinology, healing, desquamation, depigmenting, and also for macrophage activation (Shah S et. al., 2006) .
Chemistry of Sophorolipids
Sophorolipids can only be synthesized by a select number of yeast species as they are known to be surface-active compounds . e non-pathogenic yeast, Candida bombicola is used in this fermentation process in order to produce sophorolipids. Candida bombicola uses glucose as the primary carbon source, converting the fermentation medium and oil into sophorolipids. us, the sophorolipids formed has two glucose molecules. e study of the anti-cancer property of sophorolipids has so far attracted little interest from the scienti c community but recent studies on their
Shazmin Kithur Mohamed
The use of Sophorolipids as anti-angiogeneic therapy for cancer treatment e ect on the growth and apoptosis of H7402 human liver cancer cells was investigated and the agent was found to cause dose-and time-dependent inhibition of cell proliferation (Chen et al., 2006 (Wadekar et al., 2012b) .
Surfactants incorporate a variety of amphiphilic mixes with unmistakable hydrophobic and hydrophilic spaces created through engineered pathways. ese spaces prompt division especially at the interface between liquids of diverse extremity and hydrogen holding (Georgiou et al ., 1992) . e advancement of a micellar layer at the interface diminishes the free vitality of the framework by supplanting the mass particles having higher vitality . Arti cially created surfactants are o en dangerous to the environment as they are non-biodegradable. ey might bio-collect and their generation forms by-products that can be environmentally unsafe. Surfactants spill over and oil slicks are diminishing the capacity of the sea to assimilate climatic gas and to create cloud structure cores. In this manner CO2 levels are expanding and the world's albedo, the degree to which it di usely re ects light from the sun, is diminishing. Fixing ecological regulations and expanding public concern over the need to secure biological systems have brought about an expanding enthusiasm for biosurfactants as could be allowed distinct options for compound inferred surfactants. As far as the reduction in interfacial pressure potential, numerous biosurfactants have been coordinating quality to the manufactured surfactants, which are essentially delivered from petrochemicals. Moreover, the synthetic assortment of biosynthetic amphiphilic mixes o ers a wide choice of surface-dynamic operators, which may be helpful for particular applications.
On the other hand, because of specialized or monetary limitations, biosurfactants are, as of yet, not generally used in industry (Fiechter, 1992a and 1992b) . is issue however is changing as the raising costs of fossil fuels and evident absence of predictable successful option essential assets . Also, new oil wells are being added to the pipeline at a slower rate in recent years. Unexpectedly, biosurfactants, which are completely and quickly biodegradable, have promising applications particularly in zones of ecological dangers concerning bioremediation and the scattering of oil slicks (West and Harwell, 1992; Harvey et., al 1990) . Along these lines, the era and usage of biosurfactants might change in the coming years.
Potential use of sophorolipids in angiogenesis-based diseases
Angiogenesis implies the development of novel blood vessels from the original vessels. It is a critical procedure that occurs in the body while both healthy and ill. Angiogenesis occurs in the body during wound healing, development and for restoring blood stream to tissues a er damage or a ront. e healthy body controls angiogenesis through a series of "on" and "o " switches.
At the point when pro-angiogenic cues are in greater abundance over angiogenesis inhibitors, the balance is tipped toward vessel formation. Conversely, when inhibitors are in abundance over pro-angiogenic signals, angiogenesis is ceased. e normal, healthy body maintains a perfect balance of angiogenesis modulators. When all is said and done, angiogenesis is then sharper turned "o " by the generation of a larger number of inhibitors, thus tipping the scale towards anti-angiogenesis. In numerous genuine illnesses, the body loses control over angiogenesis (Harris, 1997) . Angiogenesis-subverting illnesses arise when novel vessels either become unreasonable or de cientl. Uncontrolled angiogenesis occurs in maladies, for example, disease, diabetic visual impairment, age-related macular degeneration, rheumatoid joint in ammation, psoriasis, and more than 70 di erent conditions. In these conditions, fresh recruits vessels bolster diseased tissues, decimate typical tissues, and due to their presence, the new vessels permit tumor cells to escape into the blood ow and metastasize to di erent organs (Harris, 1997) .
Exorbitant angiogenesis happens when unhealthy cells over-produce pro-angiogenic compounds, thus overpowering the e ects of normal angiogenesis inhibitors. Anti-angiogenic treatments that will halt this fresh blood vessel development are being produced to treat these conditions. Inadequate angiogenesis can also happen in various maladies, for example, coronary conduit infection, stroke, and deferred injury mending. In these conditions, improper veins develop, and blood dissemination is not appropriately 
Conclusion
In conclusion, sophorolipids are an interesting avenue of research in the eld of anti-angiogenesis based medicine to treat a plethora of ailments. Compared with regular chemotherapeutic agents that a ect all rapidly dividing cells in the body, being able to treat patients with an environmentally safe compound that inhibits angiogenesis, thus not greatly a ecting healthy tissue since blood vessels are already formed, could be a radically di erent way to treat cancers and other maladies. Sophorolipids have been shown to halt cancer cell line growth and induce cell death.
It will be interesting to explore if sophorolipids have this same e ect on normal healthy tissue and how they could be used to treat patients in the future in order to stray away from the use of synthetic chemicals in the treatment of human illnesses.
